Atlas Trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001

Clinical trial NCT06331728 · COMPLETED

Trial details

NCT number
NCT06331728
Sponsor
IgGenix Australia Pty Ltd
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Peanut Allergy
Start date
2024-09-01
Primary completion
2025-11-06
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.